Back
to BiopharmaceuticalGlossaries.com
You are here > Biopharmaceutical
Glossary
Homepage > Drug discovery & development >
Therapeutic areas: Cardiovascular, CNS, Immunology, Infectious, Inflammation
Therapeutic indications: SCOPE
NOTE: cardiovascular:
Antibacterial Discovery and Development
September 26-27, 2018
Boston, MA
Program |
New discovery platforms, novel screens and approaches are vital for the
discovery of new antibacterials and for ceasing the dangerous trends of
multidrug microbial resistance. Gram-negative bacteria are one of the main
challenges for the healthcare system and public health in general.
Gram-negative bacteria have specific scientific problems such as low
permeability of the outer membrane that must be overcome, complicated and
multiple resistance mechanisms, etc. autistic disorder:
A
disorder beginning in childhood. It is marked by the presence of markedly
abnormal or impaired development in social interaction and communication and a
markedly restricted repertoire of activity and interest. Manifestations of the
disorder vary greatly depending on the developmental level and chronological age
of the individual. (DSM-V) MeSH Medical Subject Headings Year introduced:
1981(1966)
Autoimmune and Inflammation Drug Targets
September 27-28, 2018 Boston, MA
Program
biodefense:
Biodefense World Summit 2019 June, San Diego CA
https://www.biodefenseworldsummit.com/
pathogen detection, point-of-care, biosurveillance, sample prep
technologies, and bio recovery. blood
brain barrier: See Drug Delivery blood
brain barrier
blood substitutes:
Human
blood, plasma and tissue contain many proteins, the extraction and purification
of which are of great medical and economic importance. Transmission of
infectious diseases via blood transfusion, tissue implantation and the use of
processed blood plasma and components have placed a high priority on the
development of new strategies for safeguarding the health of millions of
patients who receive blood and tissue-derived products every year. The screening
of blood for the detection of infectious agents is continuing to advance but is
complicated by the presence of new and emerging pathogens. In addition, cost-
effectiveness and the threat of emerging and/or crossover infective agents
must also be considered.
BSE: Bovine spongiform encephalopathy (or mad cow disease). See
also TSE CJD Creutzfeldt- Jakob disease:
Related terms: BSE, blood & blood substitutes, TSE
Transmissible Spongiform Encephalopathy Narrower term:
vCJD Variant Creutzfeldt-Jakob disease
cardiac
disease:
Guidance for industry, Somatic cell therapy for, FDA
2010
Guidance for Industry -
FDA
cardiovascular
models:
Theoretical representations that simulate the behavior or activity
of the cardiovascular system, processes, or phenomena; includes the use of
mathematical equations, computers and other electronic equipment. MeSH 1980
CNS Targets June 18=19 2019,
Boston MA
https://www.pharmaweek.com/Translational-Strategies-CNS/
A greater understanding of CNS related disease biology and the emergence
of new, improved targets and technologies is bringing renewed interest,
excitement and investment into this transformative area of medicine.
Cambridge Healthtech Institute’s CNS
Targets and Translational Strategies conference
focuses on the key issues of CNS drug development – including CNS target
discovery and validation, biomarkers, bridging the preclinical/ clinical
translation gap, evaluating the strengths and weaknesses of current
preclinical models, challenging “gold-standards”, understanding mechanism
of action, dose selection, neuroimaging, neuroinflammation,
neuroimmunology, and more
CNS and Neurodegenerative Targets
September 26-27, 2018
Boston, MA
Program | The
identification of therapeutic targets based on novel mechanistic
approaches is urgently needed for CNS and neurodegenerative diseases,
particularly for conditions such as Alzheimer’s which represent extensive
unmet medical need and blockbuster potential for the right therapy.
Driven by an improving understanding of CNS disease biology and the
emergence of new mechanisms and targets, Cambridge Healthtech Institute’s
CNS and Neurodegenerative Targets conference profiles the latest tools,
targets and platforms driving today’s CNS drug discovery strategies, with
critical updates and findings in key areas such as new targets for
misfolded proteins, tau, GCPRs, kinase inhibitors, genetics, gene therapy,
and neuroinflammation.
cosmetic psychopharmacology:
https://en.wikipedia.org/wiki/Cosmetic_pharmacology
Peter Kramer, Listening to Prozac, Wikipedia http://en.wikipedia.org/wiki/Peter_D._Kramer
emerging infectious diseases: See
Scope Note Emerging Infectious Diseases,
CDC, US http://www.cdc.gov/ncidod/eid/about.htm
published monthly
Gram Negative Pathogens Targeting
September 27-28, 2018
Boston, MA
Program |
Multidrug-resistant Gram-negative bacteria are one of the main challenges
for the healthcare system and public health in general. Gram-negative
bacteria have specific scientific problems, such as low permeability of
the outer membrane that must be overcome, complicated and multiple
resistance mechanisms, etc. immunogenetics:
Concerns
that branch of genetics that deals with the genes which regulate the immune
response. Immunogenetics arose in the 1960s born out of interest in the human
leucocyte antigens (HLAs) and their role in transplant acceptance and rejection.
The idea that the immune response is under genetic control however predates the
clinical need to study HLA, and its origins can be traced back to earlier in the
20th century, with truly great scientists (Landsteiner, Gorer, Snell, Medawar,
and Dausset, to name but a few). (Current and up to date. Immunogenetics was
never a science that was restricted to studies of HLA. The ABO blood groups,
immunoglobulin, and complement gene polymorphisms have long been included in the
list. More recently, however, we have come to understand the extent of
polymorphism in the human genome, and have realised almost any gene that encodes
an immune active product can act as an “immune response gene.”
…
Most
studies to date have been concerned with the human MHC, but an increasing number
of investigators are now focussing on other immunogenes that affect both innate
and acquired immunity to self and foreign antigens.
P
T Donaldson, Genetics of liver disease:
immunogenetics and disease pathogenesis, Gut.
2004
April; 53(4):
599–608 doi:
10.1136/gut.2003.031732
immunogenomics
The
immunogenomics data analysis working group (IDAWG) is an international
collaboration
of histocompatibility
and immunogenetics investigators who
share the goal of facilitating the sharing of immunogenomic data (HLA, KIR,
etc.) and fostering the consistent analysis and interpretation of those data by
the immunogenomics community and the larger genomics communities.
The
working group was formed in advance of the 16th
International HLA and Immunogenetics Workshop (IHIW) and Conference with
the intent to present its recommendations on topics of data-management and
data-analysis at the 16th IHIW and Conference in 2012. IDAWG projects continue
in anticipation of the 17th IHIW meeting to be held in 2017.
http://www.immunogenomics.org/
immunological
models:
Theoretical representations that simulate the behavior or activity
of immune system, processes, or phenomena. They include the use of mathematical
equations, computers, and other electrical equipment. MeSH 1995
Immunomodulatory Therapeutic Antibodies
Autoimmune,
Infectious and Neurological Diseases August
13-14, 2020 Boston, MA
With the incidence of age-related neurodegenerative diseases expected to
increase significantly over the next decade, the challenge of effectively
treating autoimmune diseases, and the continuing issue of infectious diseases
remaining a leading cause of mortality worldwide, new treatment strategies are
urgently needed. In many cases, the best hope for better health outcomes lies in
exploiting the immune system to achieve therapeutic effect.
https://www.immuno-oncologysummit.com/Immunomodulatory-Antibodies-Cancer/
immunotherapy: Biologics
immunotherapy cancer
infectious disease
models:
Models of Infectious Disease Agent Study (MIDAS) is a collaboration
of research and informatics groups to develop computational models of the
interactions between infectious agents and their hosts, disease spread,
prediction systems and response strategies. The models will be useful to
policymakers, public health workers and other researchers who want to
better understand and respond to emerging infectious diseases. If a disease
outbreak occurs, the MIDAS network may be called upon to develop specific models
to aid public officials in their decision-making processes. National Institute
of General Medical Sciences, NIH
https://www.nigms.nih.gov/research/specificareas/MIDAS/pages/default.aspx infectious disease
ontology:
http://infectiousdiseaseontology.org/page/Main_Page
Inflammation Inhibitors
Medicinal Chemistry
for Oral-Based Autoimmune and Inflammation Related Therapeutics lipoproteomics:
Karlsson H, Leanderson P, Tagesson C, Lindahl M, Lipoproteomics
I: mapping of proteins in low-density lipoprotein using two- dimensional gel
electrophoresis and mass spectrometry Proteomics. 5(2): 551-65, 2005 Feb Related term: cardiogenomics
microbial proteomics:
Bacterial genomes encode all possible
virulence determinants, vaccine candidates, and potential drug targets. Further,
a completed genomic sequence establishes a basis for high throughput analysis of
the proteins expressed (i.e., the proteome). Respiratory pathogens have been
among the first to have their genomes entirely sequenced.
Molecular Diagnostics for Infectious Disease
March 2-4, 2020 San Francisco, CA
| Advancing
Molecular Diagnostics to Improve Detection and Patient Outcome
With NGS assays moving into clinical use and
new technologies being developed for a host of infectious diseases, it is
more important than ever to keep on top of the latest advances in the
field. Cambridge Healthtech Institute’s 4th Annual Molecular Diagnostics
for Infectious Disease symposium will discuss in detail the process of
moving sequencing into clinical use, with an examination of reference vs.
clinical labs, metagenomics vs. panel-based tests, investments in
bioinformatics, and physician education. We will also examine rapid
susceptibility testing in the light of the new breakpoints, how they are
used, and the role genotypic vs. phenotypic testing. Special attention
will also be paid to new technologies for host response and clinical
applications of microbiome analysis. We will also have a discussion
centered around the regulatory landscape for NGS diagnostics and what to
expect as we will look into the future of molecular diagnostics for
infectious disease.
NASH and Fibrosis
September 17-18, 2019 Boston, MA
|
Drug development for the fatty liver
Non-alcoholic Steatohepatitis (NASH) is a disease of the liver that starts
with an accumulation of fat and proceeds to inflammation and scarring of
the liver. The scarring begins as fibrosis, but can worsen to cirrhosis
and eventual liver failure. The global incidence of NASH is rapidly rising
and no medical treatments exist. Advances in the scientific understanding
of the fibrotic disease process in other organs are also rapidly
occurring.
NeuroCommons:
The NeuroCommons project seeks to make all scientific research materials -
research articles, knowledge bases, research data, physical materials - as
available and as usable as they can be. We do this by fostering practices
that render information in a form that promotes uniform access by
computational agents - sometimes called "interoperability".
http://neurocommons.org/page/Main_Page
neurological
models: Theoretical representations that simulate the behavior or activity of
the neurological system, processes or phenomena; includes the use of
mathematical equations, computers, and other electronic equipment. MeSH 1977
neuropharmaceuticals:
Drugs targeting the central nervous systems. The blood brain barrier poses
a formidable drug delivery challenge. Related
terms: cogniceuticals, neuroceuticals, neuroinformatics
neuroproteomics:
now proteomics gives way to neuroproteomics as we begin to
unravel the complex mysteries of neurological diseases that less than a
generation ago seemed opaque to our inquiries, if not altogether intractable.
... Bolstered by each new discovery, researchers employing multiple methods
of inquiry gain a deeper understanding of the key biological problems related to
brain function, brain structure, and the complexity of the nervous system. …
Approaches discussed in the book include mass spectrometry, electrophoresis,
chromatography, surface plasmon resonance, protein arrays, immunoblotting,
computational proteomics, and molecular imaging. Neuroproteomics Frontiers
in Neuroscience Edited by Oscar Alzate, CRC Press 2010 http://www.ncbi.nlm.nih.
Protein profiling related to CNS
cells, tissues and neurodegenerative and neuropsychiatric conditions.
Neurotech Investing & Partnering
Conference 2020 May 5-6 Boston MA
keynotes, investor panels, cutting-edge company presentations and a
comprehensive selection of neurotech topics.
https://www.neurotechpartnering.com/ phyloproteomics:
Identification of unknown bacterial isolates based on similarities within protein
biomarker databases. [Gregory C. Conway et. al. "Phyloproteomics: Species Identification of
Enterobacteriaceae Using Matrix- Assisted Laser Desorption/ Ionization
Time- of- Flight Mass Spectrometry" J. Mol. Micro. Biotechnol. 3: 103-112,
2001 PrPC proteins:
Normal cellular isoform of prion proteins (PRIONS) encoded by a chromosomal gene and found in normal and
scrapie- infected brain tissue, and other normal tissue. PrPC are protease-
sensitive proteins whose function is unknown. Post-
translational modification of PrPC into PrPSC leads to infectivity.
MeSH, 1995 PrPSc proteins:
Abnormal isoform of prion proteins (PRIONS) resulting from a posttranslational modification of the cellular prion protein (PRPC PROTEINS). PrPSc are disease-specific proteins seen in certain human and animal neurodegenerative diseases (PRION DISEASES).
MeSH, 1995 psychogenomics:
Used here to describe the process of applying the powerful tools of genomics and
proteomics to achieve a better understanding of the biological substrates of
normal behavior and of diseases of the brain that manifest themselves as
behavioral abnormalities. Applying psychogenomics to the study of drug addiction
will lead to the identification of genes and their protein products that control
the reward pathways of the brain and their adaptations to drugs of abuse, as
well as variations in these genes that confer genetic risk for addiction and
related disorders. EJ Nestler, Psychogenomics: opportunities for understanding
addiction, J Neurosci. 21(21): 8324- 8327, Nov 1, 2001 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11606619&query_hl=38 psychoneuroimmunology:
The Psychoneuroimmunology Research Society is an
international organization for researchers in a number of scientific and medical
disciplines including psychology, neurosciences, immunology, pharmacology,
psychiatry, behavioral medicine, infectious diseases, endocrinology and
rheumatology, who are interested in interactions between the nervous system and
the immune system, and the relationship between behavior and health. https://www.pnirs.org/index.cfm
Related terms: neuroimmune network,
neuroimmunoendocrinology, neuroimmunomodulation
systems
immunotechnology
Our group’s overall research interests are in the
emerging field of experimental systems immunology, which is at the intersection
of molecular biotechnology and immunology. Research in systems immunology is
focused on gaining a more comprehensive and quantitative understanding of the
immune system. This includes the use of high-throughput molecular technologies
such as next generation DNA sequencing, quantitative proteomics, bioinformatics,
and protein engineering. These approaches enable us to develop an immunological
toolbox capable of addressing a wide spectrum of human diseases. For example,
immunoglobulin repertoires (antibodies and TCRs) can be quantitatively profiled
by high-throughput DNA sequencing and quantitative proteomics. These tools are
providing an unprecedented level of information depth on the distribution of
adaptive immune cell functionalities and diversity, which develop upon
activation following vaccination, pathogenic infection, or disease.
Therapeutic indications resources
Insight
Pharma Reports therapeutic indications
https://www.insightpharmareports.com/therapeutic-indications
Cardiovascular, CNS & neurology, Immunology,
Infectious diseases, Inflammation
glossary & taxonomy
Evolving Terminologies for Emerging Technologies
Comments? Questions?
Revisions?
Mary Chitty MSLS
mchitty@healthtech.com
Last revised
January 08, 2020
<%end if%>
CNS & Neurology Alzheimer's, autism, blood brain
barrier, neurodegenerative
Immunology: autoimmune, diabetes, inflammation
Infectious diseases: antibacterials, antivirals, blood substitutes
Drug
discovery term index Informatics
term index Technologies term
index Biology term index
Related glossaries include Cancer Drug
discovery & development Drug safety
& Pharmacovigilance Molecular
& Predictive Medicine
antivirals:
Antivirals: Targeting HBV and Beyond
September 25, 2018 Boston,
MA
Program
Antiviral drug development is shifting its focus to hepatitis B virus (HBV)
after the encouraging success of developing direct-acting antivirals against the
hepatitis C virus. Both viruses cause liver disease and represent major global
health problems that can lead to death from liver failure. Much of the research
focuses on broadly applicable antiviral approaches that modulate the host’s
immune system or other infection response processes. Host immunomodulatory
strategies are also being applied for treating emerging viral diseases. Progress
has also been made in several HBV-specific approaches such as RNAi to silence
HBV gene production, or inhibit the virus’ capsid assembly, which are in
early-stage clinical trials or may be soon.
Wikipedia
http://en.wikipedia.org/wiki/Biodefense
infectious disease
diagnostics:
Advanced Diagnostics for Infectious
Disease May 2019 • Lisbon Portugal Program |
Recent advances in technology have rapidly changed the landscape of infectious
disease diagnostics. Novel technologies (and new uses for already standard
technologies!) such as next-generation sequencing (NGS) and mass spectrometry
are changing the way that researchers perform rapid diagnostics and detect
antimicrobial resistance.
neuroceuticals: http://economistsview.typepad.com/economistsview/2006/02/neuroceuticals.html Related
terms: cogniceuticals, neuropharmaceuticals
prion:
Small proteinaceous
infectious particles which resist inactivation by procedures that modify nucleic
acids and contain an abnormal isoform of a cellular protein which is a major and
necessary component. The abnormal (scrapie) isoform is PrPSc (PRPSC PROTEINS)
and the cellular isoform PrPC (PRPC PROTEINS). The primary amino acid sequence
of the two isoforms is identical. Human diseases caused by prions include
CREUTZFELDT- JAKOB SYNDROME and GERSTMANN- STRAUSSLER SYNDROME. MeSH, 1986 Related terms: BSE, CJD, National Prion Disease Pathology
Surveillance Center NPDPSC, PrP, TSE, vCJF
Therapeutic indications Conferences:
http://www.healthtech.com/Conferences/Search.aspx?k=&r=&s=RXXS
Therapeutic indications CDs, DVDs http://www.healthtech.com/Conferences/CompactDiscSearch.aspx?k=&r=&s=RXXS
Therapeutic indications Short courses http://www.healthtech.com/Conferences_Upcoming_ShortCourses.aspx?s=RXXS
How
to look for other unfamiliar terms
Back to GenomicGlossaries.com